SUPERNUS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
SUPN$27.62+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders' Equity
Years Ended December 31, 2021, 2022 and 2023
(in thousands, except share data)
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveEarnings (Loss) · RetainedEarnings(AccumulatedDeficit) · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance, December 31, 2020 | 52,868,482 | $53 | $409,332 | $8,975 | $326,498 | $744,858 |
| Share-based compensation expense related to employee stock purchase plan and share-based awards | — | — | 17,910 | — | — | 17,910 |
| Issuance of common stock related to employee stock purchase plan and share-based awards | 387,612 | — | 7,095 | — | — | 7,095 |
| Net earnings | — | — | — | — | 53,424 | 53,424 |
| Unrealized loss on marketable securities, net of tax | — | — | — | (7,436) | — | (7,436) |
| Balance, December 31, 2021 | 53,256,094 | 53 | 434,337 | 1,539 | 379,922 | 815,851 |
| Cumulative effect of adoption of ASU 2020-06 | — | — | (56,212) | — | 40,612 | (15,600) |
| Balance, January 1, 2022 | 53,256,094 | 53 | 378,125 | 1,539 | 420,534 | 800,251 |
| Share-based compensation expense related to employee stock purchase plan and share-based awards | — | — | 17,568 | — | — | 17,568 |
| Issuance of common stock related to employee stock purchase plan and share-based awards | 997,702 | 1 | 12,422 | — | — | 12,423 |
| Net earnings | — | — | — | — | 60,711 | 60,711 |
| Unrealized loss on marketable securities, net of tax | — | — | — | (4,749) | — | (4,749) |
| Balance, December 31, 2022 | 54,253,796 | 54 | 408,115 | (3,210) | 481,245 | 886,204 |
| Share-based compensation expense related to employee stock purchase plan and share-based awards | — | — | 26,759 | — | — | 26,759 |
| Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld | 469,560 | 1 | 4,619 | — | — | 4,620 |
| Net earnings | — | — | — | — | 1,316 | 1,316 |
| Unrealized gain on marketable securities, net of tax | — | — | — | 2,617 | — | 2,617 |
| Balance, December 31, 2023 | 54,723,356 | $55 | $439,493 | $(593) | $482,561 | $921,516 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.